Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

21 Mar 2022

• By Joseph Haas

New cancer discovery — Bristol gets first approval for new checkpoint immunotherapy, LAG-3 • Source: Alamy

Related Content

ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations

07 Jun 2021

BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients

20 May 2021

Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

04 Nov 2020

BMS Jumps Ahead With LAG-3 Melanoma Data

25 Mar 2021

Nine Major Approval Decisions To Watch In Early 2022

27 Jan 2022

Bristol’s Growth Plan Faces First Test In 2022

04 Feb 2022

Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space

06 Apr 2018

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Immutep S.A.

Novartis AG

Pfizer Inc.

Incyte Corporation

Additional Topics

Approvals ImmunoOncology Business Strategies Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.